medigraphic.com
ISSN 1561-3011 (Digital)

2013, Número 2

<< Anterior Siguiente >>

Rev Cubana Invest Bioméd 2013; 32 (2)


Detección inmunohistoquímica del receptor del factor de crecimiento epidérmico: revisión de algunos aspectos técnicos relacionados

Blanco SR, Cedeño AM, Rengifo CE

Idioma: Español
Referencias bibliográficas: 50
Paginas: 230-242
Archivo PDF: 70.39 Kb.


RESUMEN

Introducción: En los últimos años la inmunohistoquímica (IHQ) se ha convertido en el método más usado en la determinación de la expresión del receptor del factor de crecimiento epidérmico (REGF). La falta de control de algunos aspectos técnicos durante su determinación en muestras de tejidos fijados en formol e incluidos en parafina, como por ejemplo, la fijación tisular y el procesamiento de las muestras, la elección de un método adecuado de reanimación antigénica, el empleo de diferentes anticuerpos anti-REGF y sistemas de detección, a llegado a tal punto que la confiabilidad y reproducibilidad de la detección inmunohistoquímica de la sobreexpresión del REGF está siendo fuertemente cuestionada.
Objetivo: La estandarización de estos procedimientos constituye una de las metas más perseguidas actualmente, con el objetivo de continuar empleando la sobreexpresión del REGF por IHQ como criterio de elección y predictor de la respuesta al tratamiento, sin necesidad de recurrir a técnicas más complejas para su detección, disminuyendo en gran medida a la variabilidad intra e interlaboratorios.
Métodos: Revisión y determinación de la pertinencia en el control de la técnica investigativa y viabilidad de la misma.
Conclusiones: La determinación de la sobreexpresión del REGF por IHQ continúa siendo el método más empleado actualmente como predictor de la respuesta a la terapia contra el receptor. La heterogeneidad de las muestras, la falta de estandarización de los procedimientos inmunohistoquímicos empleados, la existencia de numerosos protocolos con un mismo fin, así como otras fuentes de variabilidad, han conducido a la obtención de resultados poco confiables y reproducibles.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ramos-Vara JA. Principles and methods of immunohistochemistry. Methods Mol Biol. 2011;691:83-96.

  2. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Annals of Oncology. 2006;17(6):1007-13.

  3. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, et al. Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. Clin Cancer Res. 2010;16(8):2474-82.

  4. Mascaux C, Wynes MW, Kato Y, Tran C, Reyna Asuncion B, Zhao JM, et al. EGFR Protein Expression in NonSmall Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor- A Novel Antibody for Immunohistochemistry or AQUA Technology. Clin Cancer Res. 2011;17(24):7796-807.

  5. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer. Br J Cancer. 2007;96(6):857-63.

  6. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160-74.

  7. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009;1(1):41-8.

  8. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9-15.

  9. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck. 2001;23(2):147-59.

  10. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir. J 2002;20(4):975-81.

  11. Lee HJX. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008;14(7):2088-94.

  12. Mariezkurrena XA, Guimerá JA, Rodríguez JW, Weisman R, Ongkeko W. Immunohistochemistry study of EGFR expression in head and neck squamous cell carcinoma. Acta Otorrinolaringol Esp. 2005;56(4):143-6.

  13. Yarom N, Marginean C, Moyana T, Gorn-Hondermann I, Birnboim HC, Marginean H, et al. EGFR expression variance in paired colorectal cancer primary and metastatic tumors. Cancer Biol Ther. 2010;10(5):416-21.

  14. Mohammadi G, Jamialahmasi K, Lary S, Chaffarzadegan K. Expression of membranous epidermal growth factor receptor in colorectal adenocarcinoma and it´s correlation with clinicopathological features. Pak J Biol Sci. 2011;14(5):357-62.

  15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-45.

  16. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201-8.

  17. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23(9):1803-10.

  18. Huertas Fernández MJ, Rodríguez Mateos ME, Gómez Reina MJ, Martínez Bautista MJ, Sánchez Martínez I. Treatment with cetuximab in metastatic colorectal cancer patients who do not express the epidermal growth factor receptor. Farm Hosp. 2007;31(5):264-9.

  19. Saltz LB. Biomarkers in colorectal cancer: added value or just added expense. Expert Rev Mol Diagn. 2008;8(3):231-3.

  20. Derecskei K, Moldvay J, Bogos K, Timar J. Protocol Modifications Influence the Result of EGF Receptor Immunodetection by EGFR pharmDxTM in Paraffin-Embedded Cancer Tissues. Pathology Oncology Research. 2006;12(4):243-6.

  21. Díaz A, Lage A. Terapias con inhibidores del receptor del factor de crecimiento epidérmico: acercando el futuro. Biotecnología Aplicada. 2007;24:1-9.

  22. Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs. 2005;16(5):483-94.

  23. Ferguson KM. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys. 2008;37:353-73.

  24. Li F, Liu Y, Chen H, Liao D, Shen Y, Xu F, et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features» J Exp Clin Cancer Res. 2011;30:27.

  25. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol. 2010;2:13.

  26. Shawarby MA, Al-Tamimi DM, Ahmed A. Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients. Diagn Pathol. 2011;6:57.

  27. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, et al. Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator. Cancer Res. 2009;69(6):2540-9.

  28. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncol. 2007;43(2):193-8.

  29. Viloria-Petit A, Rengifo-Calzado E. Antiepidermal growth factor receptor antibody: immunonohistochemistry. En: MA Hayat, ed. Handbook of immunohistochemistry and in situ hybridization oh human carcinomas. Elsevier Academic Press. 2005;8:79-101.

  30. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14(3):840-6.

  31. Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol. 2002;29(14):45-54.

  32. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52(7):893-901.

  33. Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, et al. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep. 2006;16(6):1173-9.

  34. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The Biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10(12 Pt 2):4227-32.

  35. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al. Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib. J Natl Cancer Inst. 2005;97(12):880-7.

  36. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev. 2009;35(3):262-71.

  37. Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 2010;10:376.

  38. Miller RT, Swanson PE, Wick MR. Fixation and Epitope Retrieval in Diagnostic Immunohistochemistry: A Concise Review with Practical Considerations. Appl Immunohistochem Mol Morphol. 2000;8(3):228-35.

  39. Torp SH, Bringedal K, Dalen A. Immunohistochemical detection of epidermal growth factor receptor in human high-grade astrocytomas a comparision between frozen and paraffin sections. J Exp Clin Cancer Res. 2005;24(1):89-92.

  40. Montero C. The antigen-antibody reaction in immunohistochemistry. J Histochem Cytochem. 2003;51(1):1-4.

  41. Sompuram SR, Vani K, Hafer LJ, Bogen SA. Antibodies immunoreactive with formalin-fixed tissue antigens recognize linear protein epitopes. Am J Clin Pathol. 2006;125(1):82-90.

  42. Sompuram SR, Vani K, Messana E, Bogen SA. A molecular mechanism of formalin fixation and antigen retrieval. Am J Clin Pathol. 2004;121(2):190-9.

  43. Shi SR, Cote RJ, Taylor C. Antigen Retrieval Techiques: Current Perspectives. J Histochem Cytochem. 2001;49(8):931-7.

  44. Taylor CR, Shi SR, Cote RJ. Antigen retrieval for immunohistochemistry. Status and need for greater standardization. Appl Immunohistochem. 1996;4:144-66.

  45. Dako Cytomation. EGFR pharmDxTM Package Insert Carpinteria, CA. Dako; 2004.

  46. Banerjee D, Guha AK, Guindi MM, Haliotis T, Hanna W, Jass JR, et al. Best Practice Standards for EGFR Testing in Colorectal Cancer in Canada. Canadian Consensus Panel on EGFR Testing in Colorectal Cancer. 2005.

  47. Kersting C, Packeisen J, Leidinger B, Brandt B, Von Wasielewski R, Winkelmann W, et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol. 2006;59(6):585-90.

  48. Bhargava R, Chen B, Klimstra DS, Saltz LB, Hedvat C, Tang LH, et al. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer. 2006;106(8):1857-62.

  49. Tse C, Treaba DO, Goldstein LC, Kandalaft PL, Barry TS, Gown AM. Sensitivity of immunohistochemical detection of EGFR could impact patient eligibility for anti-EGFR therapy. Journal of Clinical Oncology. ASCO Annual Meeting Proceedings 2005;23(16S):3607.

  50. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVisionTM+ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMateTM, CSA, LABC, and SABC Techniques. J Clin Pathol. 1998;51(7):506-11.




2020     |     www.medigraphic.com